HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, official symbol HMGCR) is the rate-controlling enzyme (NADH-dependent, EC 1.1.1.88; NADPH-dependent, EC 1.1.1.34) of the mevalonate pathway, the metabolic pathway that …

2024年12月25日 · HMGCR (3-Hydroxy-3-Methylglutaryl-CoA Reductase) is a Protein Coding gene. Diseases associated with HMGCR include Muscular Dystrophy, Limb-Girdle, Autosomal Recessive 28 and Low Density Lipoprotein Cholesterol Level Quantitative Trait Locus 3. Among its related pathways are superpathway of cholesterol biosynthesis and Metabolism of steroids.

胆固醇合成主要发生在肝脏，通过近30步酶促反应将乙酰辅酶a转化为胆固醇分子；其中3-羟基-3-甲羟基戊二酰辅酶a还原酶（ hmgcr ）和鲨烯单加氧酶（sm）是内源合成途径的两个限速酶。新产生的胆固醇与甘油三酯组装成极低密度脂蛋白（vldls）分泌到血液中或以 ...

2024年5月9日 · HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase,3-羟基-3-甲基戊二酸单酰辅酶A还原酶,简称HMG-CoA还原酶)是由887个氨基酸残基组成的糖蛋白，存在于肝脏、肠道及其他组织的内质网。

HMGCR is differentially expressed in colorectal cancer and that positive expression is associated with favourable tumour characteristics and a prolonged survival in unadjusted analysis. HMGCR is upregulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia.

HMGCR (3-hy-droxy-3-methyl glutaryl coenzyme A reductase)-mediated mevalonate pathway is a key step in the organism’s de novo synthesis of cholesterol. Therefore, the expression and regulation of HMGCR are important for the mainte-nance of cholesterol homeostasis.

胆固醇稳态对机体正常的生命活动至关重要, 3-羟基-3-甲基戊二酸单酰辅酶A还原酶 (3-hydroxy-3-methyl glutaryl coenzyme A reductase, HMGCR)介导的甲羟戊酸途径是机体胆固醇从 头合成的关键步骤, 因此, HMGCR的表达及调控对机体胆固醇稳态的维持十分重要。在机体内, HMGCR从 ...

该基因的人类直系同源物与多种疾病有关，包括哮喘；冠状动脉疾病（多发性）；失智;糖尿病（多发性）；和神经退行性疾病（多种）。 与人 HMGCR（3-羟基-3-甲基戊二酰辅酶 A 还原酶）同源。 [由基因组资源联盟提供，2022 年 4 月] Enables identical protein binding activity and protein Phosphatase 2A binding activity.

2025年1月16日 · HMGCR is a vital rate-limiting glycoprotein enzyme within the mevalonate and isoprenoid pathways that converts 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) to mevalonate (Fig. 1).

In this review, we discuss the wide range of clinical phenotypes in myositis patients with a recently identified MSA against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). We will use the term anti-HMGCR myopathy to refer to all phenotypes associated with this disease consistent with the most recent ENMC meeting recommendations [5].